Does a Frequent Genetic Mutation Pave the Way for New Treatments Against Aggressive Breast Cancer?

Triple-negative breast cancer is one of the most aggressive and difficult-to-treat forms. It often affects younger women and carries a high risk of metastasis and recurrence. Unlike other types of breast cancer, it does not respond to standard targeted therapies, which limits treatment options for patients. However, this form of cancer has a particular feature: it is highly immunogenic, meaning it triggers a more pronounced immune response. Additionally, in nearly 80% of cases, a mutation in the TP53 gene is present. This gene, nicknamed the “guardian of the genome,” normally plays a key role in protecting against tumor development by regulating cell division and repairing damaged DNA.

When the TP53 gene is mutated, the p53 protein it produces no longer functions correctly. Instead of protecting the cell, it promotes tumor growth, treatment resistance, and metastasis formation. TP53 mutations can lead to loss of function, abnormal gain of function, or even block the action of any remaining normal p53 proteins. These mechanisms partly explain why triple-negative tumors are so resistant to conventional chemotherapies and why their prognosis remains poor.

Recent research is focusing on developing therapies that specifically target these mutations. Several approaches are being explored to restore normal p53 function or eliminate cancer cells that depend on it. Some molecules tested in laboratories and clinical trials aim to correct the defective form of the protein, prevent its abnormal aggregation, or promote its degradation. Other strategies use modified viruses to reintroduce a healthy version of p53 into tumors or stimulate the immune system to recognize and attack cells carrying the mutation.

Among the most promising avenues are drugs capable of restoring a near-normal structure to the mutated protein, such as arsenic trioxide or COTI-2. Others target cellular mechanisms that stabilize the mutated protein, such as the mevalonate pathway, or block proteins that prevent its degradation. Clinical trials are underway to evaluate the effectiveness of these treatments, alone or in combination with chemotherapy or immunotherapy. Some of these trials include patients with triple-negative breast cancer, although results are not yet available for all.

Immunotherapy also represents an encouraging approach. Since cancer cells with a TP53 mutation produce abnormally high levels of p53, they may be more vulnerable to immune system attacks. Bispecific antibodies, designed to direct T lymphocytes toward tumor cells, are currently being tested. Another approach involves using protein crystals or vaccines to reactivate the immune response against the tumor.

While these advances are still experimental, they offer real hope for patients with this aggressive form of cancer. Scientists hope that these new therapies will not only slow disease progression but also significantly improve survival and quality of life. The challenge remains significant, as each TP53 mutation may respond differently to treatments. However, the progress made in recent years suggests that targeting this mutation could be a game-changer in the fight against triple-negative breast cancer.

Legal Attributions

Study Citation

DOI: https://doi.org/10.1007/s12609-025-00618-w

Title: p53 Targeted Therapies in Triple Negative Breast Cancer

Journal: Current Breast Cancer Reports

Publisher: Springer Science and Business Media LLC

Authors: Allison Murray